Dear Editor
I read the article by Kniepeiss et al. with great interest. It describes the first attempt to significantly reduce the rate of postoperative hernia in patients who undergo liver transplantation [
1]. The technique of primary wound augmentation with the use of mesh was first described in 2002 in a group of patients subjected to a bariatric procedure [
2]. Four years later, the results of the first randomized clinical trial of hernia prophylaxis were published [
3]. The effectiveness of laparotomy closure, with the use of a non-absorbable mesh, in reduction of the rate of incisional hernia has been confirmed by many studies, among them a multicenter, double-blind, randomized controlled trial by Jairam et al. [
4].
The authors of the article published in
Trials emphasize the risk of using the mesh in patients undergoing immunosuppressive therapy. A large study comparing the use of a mesh in repairing an incisional hernia in patients who underwent liver transplantation or pancreatoduodenectomy showed similar results in both groups, although only patients with transplanted liver were receiving immunosuppressive therapy [
5].
According to data obtained from the Americas Hernia Society Quality Collaborative, immunosuppression in patients subjected to open elective ventral hernia repair is associated with an increased risk of 30-day surgical site occurrence, mostly seromas, but not surgical site infection or an additional 30-day morbidity or mortality [
6].
To reduce the risk of using the mesh in immunosuppressed patients, the authors chose a long-absorbing mesh, which maintains the mechanical strength of the wound for up to 18 months. Various studies have shown that postoperative hernia is a lifelong risk. Juvany and colleagues have found that, in half of the patients who developed incisional hernia, it occurred more than 3 years from the original procedure [
7]. Kockerling et al. proved that in a complex abdominal hernia repair, biologic and biosynthetic meshes do not provide a superior alternative to synthetic meshes [
8]. The use of poly-4-hydroxybutyrate mesh to repair incisional hernia in a high-risk group of patients, resulted in a 9% recurrence rate in the 18-month follow-up [
9]. There is no evidence to support the use of biologic/biosynthetic meshes for prevention of incisional hernias [
8].
I am afraid that the choice of an absorbable mesh may reduce the potential success rate of incisional hernia prevention in patients who undergo liver transplantation.
Yours sincerely,
Janusz Strzelczyk, MD, PhD.
Acknowledgements
Not applicable.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.